Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 125

Total 125 documents found.

  •  
  • 2010 2012 Mid R Pl2010-2012 Mid-Range Plan May 12, 2010 - Transformation for a New Takeda - Yasuchika Hasegawa President & CEO Takeda Pharmaceutical Company Limited Agenda 1 Outcome of 2006-2010 Mid-Range Plan 2 2010-2012 Mid-Range Plan 3 Forecasts for Financial Results 4 Strategic Investments and Returns to Shareholders 2 Operational targets in FY2010 and Results as of End of FY2009 Outcome of 2006-2010 Mid-Range Plan Achievements to date on 2006-2010 Mid-Range Plan Enhancement of R&D pipeline, toward sales of in-house ethical products of 2 trillion yen in FY2015 Not achieved Sales of in-house ethical products: 1.4 trillion yen Not achieved (1.2 trillion yen) Market share*: 2.5% 2.5% (Forecast) *Weighted average of countries where Takeda has its own sales channels R&D expenses: investment up to 20% of the sales of ethical products 22.1% EPS*: CAGR of more than 7% 7.8% (FY2006-FY2009) *Excluding extraordinary income/loss and other extraordinary factors ROE : Maintenance of 14 15% level 14 4% 3 Returns to Sha
  • X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Recent progress in stage ■ Discontinued project ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities - 17 - Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license MEPACT Immunostimulant (injection) Non-metastatic osteosarcoma EU Switzerland Approved (Mar 09) Approved (Nov 09) In-house SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) Diabetes mellitus (Concomitant therapy with alpha-GI) Diabetes mellitus (Concomitant therapy with thiazolidinediones) Diabetes mellitus (Concomitant therapy with Sulfonylurea) Diabetes mellitus (Concomitant therapy with Biguanide) Diabetes mellitus (Fixed-dose combination with metformin) US Jpn EU US Jpn
  • FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000099 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2010-2012 Mid-Range Plan Transformation for a New Takeda Vision Takeda's vision is to embody global pharmaceutical leadership through innovation, growth and culture guided by an unwavering commitment to significantly improve the lives of patients. Innovation based on bold leadership in science and medicine resulting in the discovery, development and delivery of high-quality, differentiated products focused on patient needs. Sustainable growth in corporate value by leveraging core therapeutic areas, and an industry-leading pipeline and product portfolio. A culture based on good corporate citizenship that empowers employees through collaboration, inclusion, trust and timely decision making. [Takeda-ism] We, the members of the Takeda G
  • SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Three Quarters (April 1 to December 31, 2009) of the Fiscal Year Ending March 31, 2010 February 3, 2010 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 15, 2010 Scheduled date of dividend payment commencement: 1. Consolidated Financial Results (April 1 to December 31, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( milli
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Three Months Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 July 31, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: August 11, 2009 1. Consolidated Financial Results (April 1 to June 30, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Three months ended June 30, 2009 378,977 (4.5) 125,630 137,594 112,594 Three months e
  • Takeda Research & DevelopmentTakeda Research & Development Strategy: To 2020 and beyond -Challenge to R&D productivity improvement and innovationShigenori Ohkawa, Ph. D Chief Scientific Officer Takeda Pharmaceutical Company Limited Executive summery The mission of Takeda R&D is to achieve better health for individuals and progress in medicine, by using cutting-edge science to develop superior pharmaceutical products that fill unmet needs. To fulfill this mission, between 2006 and 2010, we enriched our pipeline, established a global organization and enhanced our R&D capability. The 2010-2012 mid-range plan builds on these achievement and will accelerate progress toward our goal. To further enrich our R&D pipeline and grow as a global pharmaceutical company, the plan: Maximizes the value of the portfolio, mainly by emphasizing late-stage clinical programs that support near-term growth Clarifies and promote TA strategy to fulfill unmet needs by leveraging Takeda's assets Concurrently, we aim to improve efficien
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (CONSOLIDATED) Financial Results for the Fiscal Year Ended March 31, 2010 May 12, 2010 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President & CEO Contact: Hiroshi Ohtsuki, Corporate Officer, Senior Vice President, Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 25, 2010 Scheduled date of securities report submission: June 25, 2010 Scheduled date of dividend payment commencement: June 28, 2010 (Millions of yen, rounded to the nearest million) 1. Consolidated Results for Fiscal 2009 (April 1, 2009-March 31, 2010) (1) Consolidated Operating Results (Percentage figures represent changes from same period of previous
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction Whole of the pharmaceutical industry has tendency to face a number of challenges, such as stagnation in creating breakthrough novel drugs due to the difficulties of translating new innovations to products in the marketplace, and increasingly strict criteria for the approval of new drugs in advanced countries. Drastic changes in the healthcare systems are underway in many countries, by which it is anticipated that the pharmaceutical industry will be considerably affected. First of all, in the U.S., a bill of healthcare reform which aims to increase the ratio of the insured population was passed. Under the bill, pharmaceutical companies are requested to bear the burden of some portion of funds in order to finance the expansion of available health insurance by increase of the number of po
  • Takeda Receives New Information on Alogliptin (SYR-322) NDA March 6, 2009
  • OSAKA, Japan, March 6, 2009 - Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, was informed as part of regular discussions about the alogliptin New Drug Application (NDA) with the United States Food and Drug Administration (FDA), that although the alogliptin NDA was filed prior to issuance of FDA’s December 2008 guidance on new Type 2 diabetes treatments, the FDA will apply these guidelines when reviewing the alogliptin NDA.
  • Takeda Receives New Action Date for Alogliptin (SYR-322) NDA December 24, 2008
  • OSAKA, Japan, December 24, 2008 - Takeda Pharmaceutical Company Limited (“Takeda”) today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary received notification that the U.S. Food and Drug Administration (FDA) will respond to the alogliptin New Drug Application (NDA) by June 26, 2009.
  • Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. January 4, 2008
  • Osaka, Japan, January 4, 2008 --- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. submitted a new drug application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once-daily.
  • Takeda's Investigational Compound SYR-322 for Treatment of Diabetes Enters into Phase 3 Clinical Stage January 20, 2006
  • Osaka, Japan, January 20, 2006 - Takeda Pharmaceutical Company Limited ("Takeda") announced today that its investigational compound SYR-322 has entered into Phase 3 clinical stage. SYR-322 is one of the DPP4 inhibitors for the treat-ment of type 2 diabetes discovered by one of Takeda's subsidiaries in the US, Takeda San Diego, Inc. The Phase 3 studies are to be conducted globally through Takeda Global Research & Development Center Inc. using the contract research services of PPD, Inc. (Wilmington, N.C.).
  • Takeda Acquires the Rights to DPP4 Inhibitors Granted to PPD July 14, 2005
  • Osaka, Japan/Wilmington, N.C., July 14(JST) and 13(ET), 2005 --- Takeda Pharma-ceutical Company Limited ("Takeda") and PPD, Inc. (Nasdaq: PPDI) today announced an agreement in which Takeda acquired the development and marketing rights to all dipeptidyl peptidase IV (DPP4) inhibitors previously granted to PPD under an agreement between PPD and Syrrx, Inc. Takeda acquired Syrrx, Inc., now known as Takeda San Diego, Inc., in March 2005.
  • Takeda to Acquire Syrrx February 7, 2005
  • Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda", President and Chief Operating Officer: Yasuchika Hasegawa) announced today that Takeda and Syrrx Inc. (San Diego, CA, "Syrrx", Chairman of the Board: Samuel D.Colella) agreed on February 5, 2005 (PST) to merge Syrrx, Inc. into the Takeda Group. The merger is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is subject to the satisfaction of other customary closing conditions. Upon successful completion of the transaction, which is anticipated to occur in the first quarter of 2005, Syrrx will become a subsidiary of Takeda America Holdings, Inc., a wholly owned subsidiary of Takeda.

Pages:[1] [2] [3] [4] [5] [6] [7]   Next

Page Top